Press release

Certara Opens New China Office in Shanghai

Sponsored by Businesswire

Certara, a global leader in biosimulation, today announced the opening of a new office in Shanghai’s Pudong District, China’s epicenter for biopharmaceutical research and development (R&D). The office will allow Certara to strengthen its collaboration with customers in the rapidly growing Chinese biopharmaceutical industry. The company is recruiting an outstanding China-based team for business development and biopharmaceutical R&D services.

“We recognize the tremendous growth of China’s biopharmaceutical industry and are thrilled to have a direct presence in China so that we can fully support our rapidly growing Chinese customer base,” said William F. Feehery, Ph.D., CEO of Certara. “Certara’s extensive experience in biosimulation and our partnerships with top global biopharmaceutical companies will help foster innovation in China, accelerate time-to-market for our customers, and most importantly, improve patient outcomes.”

Since 2012, Certara has been holding software training workshops in China to advance the adoption of biosimulation among biopharmaceutical companies, academic institutions, and regulatory agencies. Most recently, Certara hosted an online user group meeting on its biosimulation software with more than 400 Chinese scientists.

“We appreciate Certara’s customer-focused mindset and rely on its wealth of knowledge in drug development and biosimulation,” said Ye Hua, M.D., CEO of BioNova Pharma, who has worked with Certara since 2015. “As more Chinese biopharmaceutical companies advance their discovery projects to clinical stages, they will need to adopt biosimulation to make data-driven decisions at all stages of the process. As the Chinese biopharma industry is still growing, Certara fills the gap for many China-based companies lacking biosimulation expertise and experience.”

To mark the opening of the new Shanghai office, Certara has launched a Chinese-language version of its website (

About Certara

Certara optimizes R&D productivity, commercial value and patient outcomes through its unique portfolio of model-informed drug development, regulatory science, and market access solutions. Its clients include 1,600 global biopharmaceutical companies, leading academic institutions, and key regulatory agencies across 60 countries. For more information, visit